Nurix Therapeutics Inc
NASDAQ:NRIX

Watchlist Manager
Nurix Therapeutics Inc Logo
Nurix Therapeutics Inc
NASDAQ:NRIX
Watchlist
Price: 19.9 USD -1.24%
Market Cap: 1.4B USD

Relative Value

The Relative Value of one NRIX stock under the Base Case scenario is 9.28 USD. Compared to the current market price of 19.9 USD, Nurix Therapeutics Inc is Overvalued by 53%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

NRIX Relative Value
Base Case
9.28 USD
Overvaluation 53%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
31
vs Industry
31
Median 3Y
15.1
Median 5Y
19
Industry
7.6
Forward
24
vs History
vs Industry
Median 3Y
-3.9
Median 5Y
-5.7
Industry
21.3
Forward
-6.6
vs History
vs Industry
Median 3Y
-4.9
Median 5Y
-5.7
Industry
21.2
vs History
vs Industry
Median 3Y
-4.4
Median 5Y
-5.2
Industry
23.9
vs History
7
vs Industry
26
Median 3Y
2.3
Median 5Y
2.9
Industry
2.5
vs History
31
vs Industry
32
Median 3Y
6.9
Median 5Y
10.8
Industry
7.3
Forward
15.9
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
8.7
vs History
vs Industry
34
Median 3Y
-2
Median 5Y
-3.2
Industry
4.4
Forward
-4.8
vs History
vs Industry
33
Median 3Y
-1.9
Median 5Y
-3.1
Industry
4.3
Forward
-4.3
vs History
vs Industry
34
Median 3Y
-2.6
Median 5Y
-3.1
Industry
6
vs History
vs Industry
31
Median 3Y
-2.4
Median 5Y
-2.9
Industry
4
vs History
0
vs Industry
17
Median 3Y
3.2
Median 5Y
5.7
Industry
4.4

Multiples Across Competitors

NRIX Competitors Multiples
Nurix Therapeutics Inc Competitors

Market Cap P/S P/E EV/EBITDA EV/EBIT
US
Nurix Therapeutics Inc
NASDAQ:NRIX
1.3B USD 23.7 -7.5 -4.8 -4.6
FR
Pharnext SCA
OTC:PNEXF
6T USD 38 547 500.8 -183 210.6 -222 475.9 -219 937.2
US
Abbvie Inc
NYSE:ABBV
305.6B USD 5.5 60.1 15 23.1
US
Amgen Inc
NASDAQ:AMGN
144.8B USD 4.4 34.2 16.3 30.9
US
Gilead Sciences Inc
NASDAQ:GILD
114.7B USD 4 904.3 10.1 10.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
108.5B USD 10.2 -226.3 22.4 23.5
US
Epizyme Inc
F:EPE
94.1B EUR 1 827.6 -466.4 -507.9 -494.3
AU
CSL Ltd
ASX:CSL
133.2B AUD 5.6 31.4 19.5 24.3
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
77.5B USD 5.6 16.6 15.1 16.8
US
Seagen Inc
F:SGT
39.3B EUR 17.6 -54 -58 -52.3
NL
argenx SE
XBRU:ARGX
38.4B EUR 18.1 -350 -166.6 -108.5
P/S Multiple
Revenue Growth P/S to Growth
US
Nurix Therapeutics Inc
NASDAQ:NRIX
Average P/S: 3 504 493
23.7
-5%
N/A
FR
Pharnext SCA
OTC:PNEXF
38 547 500.8
N/A N/A
US
Abbvie Inc
NYSE:ABBV
5.5
6%
0.9
US
Amgen Inc
NASDAQ:AMGN
4.4
8%
0.6
US
Gilead Sciences Inc
NASDAQ:GILD
4
3%
1.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
10.2
10%
1
US
E
Epizyme Inc
F:EPE
1 827.6
N/A N/A
AU
CSL Ltd
ASX:CSL
5.6
7%
0.8
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
5.6
7%
0.8
US
S
Seagen Inc
F:SGT
17.6
30%
0.6
NL
argenx SE
XBRU:ARGX
18.1
53%
0.3
P/E Multiple
Earnings Growth PEG
US
Nurix Therapeutics Inc
NASDAQ:NRIX
Average P/E: 209.3
Negative Multiple: -7.5
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -183 210.6 N/A N/A
US
Abbvie Inc
NYSE:ABBV
60.1
72%
0.8
US
Amgen Inc
NASDAQ:AMGN
34.2
20%
1.7
US
Gilead Sciences Inc
NASDAQ:GILD
904.3
21%
43.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -226.3
14%
N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -466.4 N/A N/A
AU
CSL Ltd
ASX:CSL
31.4
18%
1.7
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
16.6
13%
1.3
US
S
Seagen Inc
F:SGT
Negative Multiple: -54 N/A N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -350 N/A N/A
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
US
Nurix Therapeutics Inc
NASDAQ:NRIX
Average EV/EBITDA: 16.4
Negative Multiple: -4.8
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -222 475.9 N/A N/A
US
Abbvie Inc
NYSE:ABBV
15
9%
1.7
US
Amgen Inc
NASDAQ:AMGN
16.3
18%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
10.1
5%
2
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
22.4
13%
1.7
US
E
Epizyme Inc
F:EPE
Negative Multiple: -507.9 N/A N/A
AU
CSL Ltd
ASX:CSL
19.5
12%
1.6
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
15.1
11%
1.4
US
S
Seagen Inc
F:SGT
Negative Multiple: -58 N/A N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -166.6 N/A N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
US
Nurix Therapeutics Inc
NASDAQ:NRIX
Average EV/EBIT: 21.5
Negative Multiple: -4.6
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -219 937.2 N/A N/A
US
Abbvie Inc
NYSE:ABBV
23.1
24%
1
US
Amgen Inc
NASDAQ:AMGN
30.9
24%
1.3
US
Gilead Sciences Inc
NASDAQ:GILD
10.1
10%
1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
23.5
13%
1.8
US
E
Epizyme Inc
F:EPE
Negative Multiple: -494.3 N/A N/A
AU
CSL Ltd
ASX:CSL
24.3
16%
1.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
16.8
12%
1.4
US
S
Seagen Inc
F:SGT
Negative Multiple: -52.3 N/A N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -108.5 N/A N/A